Table 5.
Clinicopathological characteristics of ER+/HER2− breast cancer cohorts.
| Parameters | METABRIC Cohort | Nottingham Cohort |
|---|---|---|
| mRNA | Protein | |
| No. (%) | No. (%) | |
| Age | ||
| <50 | 228 (15) | 370 (27.7) |
| ≥50 | 1278 (85) | 967 (72.3) |
| Tumour size (cm) | ||
| <2 cm | 475 (31.5) | 789 (59.1) |
| ≥2 cm | 1031 (68.5) | 547 (40.9) |
| Grade | ||
| 1 | 166 (11.5) | 110 (8.4) |
| 2 | 707 (49.1) | 493 (37.6) |
| 3 | 565 (38.4) | 707 (54.0) |
| Nottingham Prognostic Index | ||
| GPG | 623 (41.3) | 565 (42.4) |
| MPG | 772 (51.2) | 606 (45.4) |
| PPG | 111 (7.5) | 163 (12.2) |
| Nodal stage | ||
| 1 | 404 (36.2) | 854 (64.0) |
| 2 | 634 (56.8) | 387 (29.0) |
| 3 | 78 (7) | 93 (7.0) |
| Mitosis | ||
| 1 | 734 (56.1) | |
| 2 | N/A | 267 (20.4) |
| 3 | 307 (23.5) | |
| Vascular invasion | ||
| Negative | 115 (62.8) | 916 (68.5) |
| Positive | 68 (37.2) | 418 (31.2) |
| Endocrine therapy alone | ||
| No | 234 (15.5) | 505 (37.7) |
| Yes | 384 (25.5) | 716 (53.5) |
| Other * | 888 (59) | 117 (8.8) |
| Progesterone receptor | ||
| Negative | 486 (23.2) | 308 (23.2) |
| Positive | 1020 (76.8) | 1021 (76.8) |
GPG: Good prognostic group; MPG: Moderate prognostic group; PPG: Poor prognostic group. * Include patients who received chemotherapy alone or combination of chemotherapy and endocrine therapy.